Abstract:EVT201 is a partial GABA A receptor agonist, which inhibits nervous system to treat insomnia. EVT201 can form a variety of metabolites in vivo including Ro46-1927, Ro18-5528, Ro40-9970, Ro66-9196 and Ro66-5448. This study developed a simple method to realize the simultaneous determination of EVT201 and its five metabolites by HPLC-MS/MS with an electrospray ion source (ESI). The deuterium substitute of EVT201 was chosen as the internal standard and the multiple reaction monitoring (MRM) was used for the quantification. The separation of the six compounds was accomplished with an ACE Excel 3 AQ column (50 × 2.1 mm, 3 μm, ACE). The process of protein precipitating-transferring-nitrogen blowing-reconstituting was adopted for the sample pretreatment. This method was successfully validated according to the FDA guidance. Calibration curves were linear over the concentration range of 0.100-100 ng/mL for EVT201, 0.0300-30.0 ng/mL for Ro46-1927, 0.0600-6.00 ng/mL for Ro18-5528, 0.0200-4.00 ng/mL for Ro40-9970, 0.100-20.0 ng/mL for Ro66-9196 and 0.100-20.0 ng/mL for Ro66-5448. The intra-run and inter-run precisions and accuracies were all within 14.5%. This fully validated method was successfully applied to a clinical pharmacokinetic study of EVT201 and its five metabolites in Chinese healthy subjects after the single (2.5 mg and 5 mg, N = 12) and multiple dose (2.5 mg, N = 13) administration of EVT201 capsules. The test results of 2.5 mg dose group showed that for EVT201, Ro46-1927, Ro18-5528, Ro40-9970, Ro66-9196 and Ro66-5448, the C max values (ng/mL) were 39.2 ± 9.2, 10.3 ± 1.4, 0.218 ± 0.044, 0.128 ± 0.051, 7.01 ± 1.51, 8.73 ± 3.69, respectively; the AUC 0-t values (h·ng/mL) were 231 ± 79, 143 ± 72, 10.9 ± 2.1, 1.84 ± 0.78, 55.9 ± 18.7, 135 ± 40 respectively. For EVT201, Ro46-1927, Ro66-5528, Ro66-9196 and Ro40-5448, the results of C max and AUC 0-t proved that the five compounds showed linear pharmacokinetic profile over the dose ranges of 2.5 mg to 5 mg. Meanwhile, it is the first report to evaluate the pharmacokinetic characteristics of Ro40-9970, Ro66-9196 and Ro66-5448 in human plasma. It provided meaningful parameters for the safety and tolerability evaluation of EVT201 capsules in human.

A Highly Sensitive HPLC-MS/MS Method for Quantification of 20(S)-Protopanaxadiol in Human Plasma and Its Application in Phase IIa Clinical Trial of a Novel Antidepressant Agent.

Tentative identification of 20(S)-protopanaxadiol metabolites in human plasma and urine using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

Simultaneous Determination of 20(S)-Protopanaxadiol and Its Three Metabolites in Rat Plasma by LC-MS/MS: Application to Their Pharmacokinetic Studies.

Quantification of Tripdiolide in Human Whole Blood by Liquid Chromatography Coupled with Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry.

Restricted access magnetic core-mesoporous shell microspheres with C8-modified interior pore walls for the identification of 20(S)-protopanaxadiol metabolites in rat plasma using UPLC-Q-TOF-MS/MS

Metabolic Profiles of 20(S)-Protopanaxadiol in Rats after Oral Administration Using Ultra-Performance Liquid Chromatography/quadrupole Time-of-flight Tandem Mass Spectrometry.

Application of a Validated UPLC-MS-MS Method for the Determination of Diphenidol in Biological Samples in 15 Authentic Lethal Cases.

A New Quantitation Method of Protodioscin by HPLC–ESI-MS/MS in Rat Plasma and Its Application to the Pharmacokinetic Study

A rapid and sensitive LC-MS/MS method for determination of the active component K6 in serum of patients with depression

A sensitive method for determination of platycodin d in rat plasma using liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.

A UPLC-MS/MS Assay for Simultaneous Determination of Two Antipsychotics and Two Antidepressants in Human Plasma and Its Application in Clinic.

Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Determination of Antipsychotic Drugs in Human Plasma and Its Application in Therapeutic Drug Monitoring

Integration of Stable Isotope Labeling Derivatization and Magnetic Dispersive Solid Phase Extraction for Measurement of Neurosteroids by in Vivo Microdialysis and UHPLC-MS/MS.

UPLC-MS/MS determination of 71 neuropsychotropic drugs in human serum

A simple and automated online SPE-LC-MS/MS method for simultaneous determination of olanzapine, fluoxetine and norfluoxetine in human plasma and its application in therapeutic drug monitoring

Simultaneous Determination of 32 Pyrrolizidine Alkaloids in Two Traditional Chinese Medicine Preparations by UPLC-MS/MS

Quadruplex Stable Isotope Derivatization Strategy for the Determination of Panaxadiol and Panaxatriol in Foodstuffs and Medicinal Materials Using Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry.

Development and validation of an LC-MS/MS method for simultaneous determination of EVT201 and its five metabolites in human plasma: Application to a clinical study in Chinese healthy subjects

Quantification of MDR-TB drug JBD0131 and its metabolite in plasma via UPLC-MS/MS: application in first-in-human study

A Simple and Rapid Method for the Determination of Pennogenin Diglycoside in Rat Plasma by Hplc-Ms: Application to the Pharmacokinetics of the Extract in Gongxuening Capsules

HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies.